



Tandem Diabetes Care Achieves ISO/IEC 27001:2022 Certification, Reinforcing Commitment to Global Data Security Standards

November 4, 2025

Certification affirms Tandem's company-wide commitment to cybersecurity, data protection, and operational integrity

SAN DIEGO--(BUSINESS WIRE)--Nov. 4, 2025-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it achieved ISO/IEC 27001:2022 Certification from Insight Assurance, affirming Tandem's company-wide commitment to cybersecurity, data protection, and operational integrity. As Tandem continues to expand internationally, the ISO/IEC 27001:2022 certification strengthens its position in regulated markets and simplifies compliance for partners and healthcare providers worldwide.

This press release features multimedia. View the full release here: <https://www.businesswire.com/news/home/20251104567761/en/>



Tandem Diabetes Care achieves ISO/IEC 27001:2022 Certification, reinforcing commitment to global data security standards.

The ISO/IEC 27001:2022 standard is the international benchmark for Information Security Management Systems (ISMS). It outlines the essential requirements for an ISMS, providing companies of any size and sector with a framework for establishing,

implementing, maintaining, and continually improving their data security. This certification confirms that an organization has implemented a world-class system to manage risks and secure its data, following all established best practices.

"This significant achievement demonstrates Tandem's unwavering commitment to safeguarding our customers' data and maintaining rigorous standards of information security worldwide," said John Sheridan, President and Chief Executive Officer. "I'm very proud of the cross-functional collaboration that resulted in our achievement of ISO/IEC 27001:2022 certification, which reflects the dedication, expertise, and vigilance of our entire team."

The certification followed a comprehensive audit by an independent, accredited body, evaluating Tandem's physical security systems, vendor access controls, employee training, and data management practices. To learn more about Tandem's ongoing commitment to meeting the highest independent and government-led cybersecurity and information management standards, visit <https://www.tandemdiabetes.com/legal/cybersecurity>.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ+ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit [tandemdiabetes.com](https://www.tandemdiabetes.com).

Follow @TandemDiabetesCare on TikTok and @TandemDiabetes on Facebook, Instagram, LinkedIn, and X.

Forward-looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements relate to, among other things, our current expectations to expand our business and how ISO/IEC 27001:2022 certification will help facilitate that expansion. These statements are subject to numerous risks and uncertainties, including our ability to maintain the ISO/IEC 27001:2022 certification and the risk that we may encounter other challenges that may delay our ability to expand internationally. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.

© 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem logos, Control-IQ+, t:slim X2, and Tandem Mobi are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. All third-party marks are the property of their respective owners.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251104567761/en/): <https://www.businesswire.com/news/home/20251104567761/en/>

Media Contact:

858-366-6900

media@tandemdiabetes.com

Investor Contact:

858-366-6900

IR@tandemdiabetes.com

Source: Tandem Diabetes Care, Inc.